Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 16/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14458164 | 1.00 | PDE4A (0.56) | PDE4APDE4DPDE4BPDE4CKCNH2 | |
| SCHEMBL15790463 | 0.93 | PDE4A (0.52) | PDE4APDE4DPDE4BPDE4CKCNH2 | |
| SCHEMBL6865665 | 0.88 | PDE4A (0.55) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL15753320 | 0.88 | PDE4A (0.54) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL15753322 | 0.88 | PDE4A (0.54) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL7361796 | 0.87 | PDE4D (0.51) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL15755573 | 0.85 | PDE4A (0.74) | PDE4APDE4DPDE4BPDE4CKCNH2 | |
| SCHEMBL15489502 | 0.85 | PDE4A (0.74) | PDE4APDE4DPDE4BPDE4CKCNH2 | |
| SCHEMBL2782203 | 0.84 | PDE4A (0.75) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL14165062 | 0.84 | PDE4A (0.75) | PDE4APDE4DPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090606-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-07-28 | — | — | US | disclosed |
| US-20140155428-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A (IT) | 2014-06-05 | — | — | US | disclosed |
| EP-0652868-B1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE | AVENTIS PHARMA LTD (GB) | 2004-11-10 | — | — | EP | disclosed |
| US-6255326-B1 | ANTIINFLAMMATORY AGENT; AUTOIMMUNE DISEASES | AVENTIS PHARMA LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| US-6096768-A | ADMINISTERING A 3, 5, 6-SUBSTITUTED PHENYL COMPOUND FOR THE TREATMENT OF INFLAMMATION AND AUTOIMMUNE DISORDERS | RHONE-POULENC RORER LIMITED (GB) | 2000-08-01 | — | — | US | disclosed |
| US-5935978-A | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group | RHONE-POULENC RORER LIMITED (GB) | 1999-08-10 | — | — | US | disclosed |
| US-5840724-A | COMPOUNDS FOR TUMOR NECROSIS FACTOR OR ENZYME INHIBITORS OF PHOSPHODIESTERASES | RHONE-POULENC RORER LIMITED (GB) | 1998-11-24 | — | — | US | disclosed |
| EP-0741707-B1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE POULENC RORER LTD (GB) | 1998-04-01 | — | — | EP | disclosed |
| US-5698711-A | INHIBITORS OF TUMOR NECROSIS FACTOR, CYCLIC ADENOSINE-3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE AND EOSINOPHILS | RHONE-POULENC RORER LIMITED (GB) | 1997-12-16 | — | — | US | disclosed |
| US-5679696-A | FOR INHIBITING TUMOR NECROSIS FACTOR; ENZYME INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1997-10-21 | — | — | US | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
| EP-0652868-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155428-A1 | NOVEL COMPOUNDS | PDE4A, CHRM3, PDE4B | PDE4A 1/4885PDE4D 11/4885PDE4B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.